Metal Coordination Is Crucial for Geranylgeranyl Diphosphate Synthase–Bisphosphonate Interactions: A Crystallographic and Computational Analysis[§]

Michal Lisnyansky, Elon Yariv, Omri Segal, Milit Marom, Anat Loewenstein, Nir Ben-Tal, Moshe Giladi, and Yoni Haitin

Department of Physiology and Pharmacology, Sackler Faculty of Medicine (M.L., M.M., M.G., Y.H.), Department of Biochemistry and Molecular Biology, George S. Wise Faculty of Life Sciences (E.Y., N.B.-T.), and Sackler Faculty of Medicine (O.S., A.L.), Tel Aviv University, Tel Aviv, Israel; Ophthalmology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (A.L.); and Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (M.G.)

Received June 7, 2019; accepted August 10, 2019

ABSTRACT

Geranylgeranyl diphosphate synthase (GGPPS) is a central metalloenzyme in the mevalonate pathway, crucial for the prenylation of small GTPases. As small GTPases are pivotal for cellular survival, GGPPS was highlighted as a potential target for treating human diseases, including solid and hematologic malignancies and parasitic infections. Most available GGPPS inhibitors are bisphosphonates, but the clinically available compounds demonstrate poor pharmacokinetic properties. Although the design of novel bisphosphonates with improved physicochemical properties is highly desirable, the structure of wild-type human GGPPS (hGGPPS) bound to a bisphosphonate has not been resolved. Moreover, various metal-bisphosphonate-binding stoichiometries were previously reported in structures of yeast GGPPS (yGGPPS), hampering computational drug design with metal-binding pharmacophores (MBP). In this study, we report the 2.2 Å crystal structure of hGGPPS in complex with ibandronate, clearly depicting the

involvement of three Mg^{2+} ions in bisphosphonate–protein interactions. Using drug-binding assays and computational docking, we show that the assignment of three Mg^{2+} ions to the binding site of both hGGPPS and yGGPPS greatly improves the correlation between calculated binding energies and experimentally measured affinities. This work provides a structural basis for future rational design of additional MBP-harboring drugs targeting hGGPPS.

SIGNIFICANCE STATEMENT

Bisphosphonates are inhibitors of geranylgeranyl diphosphate synthase (GGPPS), a metalloenzyme crucial for cell survival. Bisphosphonate binding depends on coordination by Mg^{2+} ions, but various Mg^{2+} -bisphosphonate-binding stoichiometries were previously reported. In this study, we show that three Mg^{2+} ions are vital for drug binding and provide a structural basis for future computational design of GGPPS inhibitors.

Introduction

Geranylgeranyl diphosphate (GGPP, C_{20}) synthase (GGPPS) is an important mevalonate pathway *trans*-prenyltransferase (Liang et al., 2002). By catalyzing the condensation of isopentenyl pyrophosphate with farnesyl diphosphate (FPP, C_{15}), GGPPS synthesizes GGPP, used for post-translational protein prenylation (Wang and Casey, 2016) (Fig. 1). Intriguingly,

although the fungal, bacterial, and plant orthologs exhibit dimeric structures, human GGPPS (hGGPPS) forms a hexamer composed of three dimers (Kavanagh et al., 2006a).

Protein prenylation is crucial for the membrane association and function of proteins essential for cellular survival. Importantly, most small GTPases, including pivotal oncogenes such as RAS and RHO, require prenylation for their normal function (Bourne et al., 1990; Konstantinopoulos et al., 2007), making inhibition of this process an attractive therapeutic target. Indeed, bisphosphonates are a group of drugs that induce cellular apoptosis by inhibiting isoprenoid biosynthesis (Kavanagh et al., 2006b). Currently, bisphosphonates are used to treat osteoporosis, a common skeletal disorder (Russell, 2011). By specifically incorporating into the bone matrix, the drug is released upon resorption by osteoclasts, undergoes endocytosis, and inhibits GGPPS, along with the upstream enzyme FPP synthase (Guo et al.,

This work was supported by Israel Science Foundation [Grants 1721/16 and 1775/12 to Y.H.], Israel Cancer Research Foundation [Grant 01214 to Y.H.], German–Israeli Foundation [Grant I-2425-418.13/2016 to Y.H.], Shtacher Foundation (to Y.H. and M.G.), Tel-Aviv Sourasky Medical Center (A.L. and M.G.), and Clair and Amedee Maratier Institute for the Study of Blindness and Visual Disorders, Sackler Faculty of Medicine, Tel-Aviv University (Y.H.).

The authors declare that no conflict of interest exists.

<https://doi.org/10.1124/mol.119.117499>.

[§] This article has supplemental material available at molpharm.aspetjournals.org.

ABBREVIATIONS: CN, coordination number; FPP, farnesyl diphosphate; GGPP, geranylgeranyl diphosphate; GGPPS, GGPP synthase; hGGPPS, human GGPPS; MBP, metal-binding pharmacophore; PDB, Protein Data Bank; TCEP, tris(2-carboxyethyl)phosphine; TEV, tobacco etch virus; WT, wild-type; yGGPPS, yeast GGPPS.

Fig. 1. Catalytic cycle of GGPPS. FPP (C_{15}) and isopentenyl diphosphate (C_5) are condensed by GGPPS to form GGPP (C_{20}). The geranylgeranyl moiety is then transferred from GGPP to a C-terminal CAA motif (C-cysteine, A-aliphatic residue, X-leucine/phenylalanine) by GGPTase (geranylgeranyl protein transferase), resulting in membrane association of small GTPases.

2007; Russell, 2011). The resultant decrease in small GTPases prenylation leads to osteoclasts apoptosis and decreased bone resorption (Russell, 2011).

The profound cellular alterations induced by inhibition of protein prenylation, and specifically, by a decrease in prenylation of small GTPases (Russell, 2011), highlighted GGPPS as a potential target for cancer therapy (Downward, 2003; Jiang et al., 2014; Mullen et al., 2016; Lacbay et al., 2018). Moreover, GGPPS enzymes from parasites leading to human diseases are considered as potential drug targets to inhibit parasitic growth in vitro and in vivo (Szabo et al., 2002; Ricci et al., 2016). However, the physicochemical properties of the marketed bisphosphonates render them with poor bioavailability and cell permeability characteristics (Lin, 1996), restricting their therapeutic scope for treatment of bone disorders, in which the drug accumulates locally and permeates the cell membrane via endocytosis during bone resorption (Russell, 2011). Thus, to exploit the full potential of GGPPS inhibition, the design of novel bisphosphonates with modified pharmacokinetic characteristics is required for expansion of their target tissues repertoire (Haney et al., 2017).

Over the past two decades, several attempts were made to establish robust computational screening approaches to predict the binding potency of bisphosphonates to GGPPS (Szabo et al., 2002; Guo et al., 2007; Haney et al., 2017). These attempts were based on the wealth of structural information obtained using the yeast GGPPS (yGGPPS) ortholog bound to various bisphosphonates (Guo et al., 2007; K-M Chen et al., 2008; Zhang et al., 2009), despite differences in the potency of these drugs toward yGGPPS and hGGPPS (Guo et al., 2007), as the structure of hGGPPS–wild-type (WT) bound to a bisphosphonate was unavailable.

We have recently determined the crystal structure of hGGPPS-D188Y, involved in bisphosphonate-induced atypical fractures, in complex with zoledronate (Lisniansky et al., 2018). Our analysis revealed the involvement of three Mg^{2+} ions in GGPPS–bisphosphonate interaction, a metal–ligand stoichiometry deviating from that observed in most previously determined yGGPPS structures (Lisniansky et al., 2018). Bisphosphonates harbor a metal-binding pharmacophore (MBP) that allows strong protein–ligand interactions mediated by coordinated metal ions (Cohen, 2017; Jiang et al., 2019). However, the use of such MBPs in drug design requires accurate positioning of metal ions in the binding site (Harding et al., 2010; Harding et al., 2018). Importantly, the assignment of Mg^{2+} ions, involved in GGPPS–bisphosphonate interactions, has proven to be especially challenging (Nayal and Di Cera, 1996; Zheng et al., 2008).

The discrepancy in the metal–ligand interaction network observed in the mutant hGGPPS, compared with previously determined yGGPPS structures, yields profound ramifications on computational drug screening and design attempts due to the different electrostatic and steric properties of the binding pocket. Indeed, exploration of the chemical space in the design of metalloenzyme inhibitors greatly depends on metal–ligand interactions (Riccardi et al., 2018). Moreover, molecular docking taking into account metal–ligand interactions has proven successful in obtaining potent and specific metalloenzyme inhibitors (Bruno et al., 2017). Therefore, we have determined the first crystal structure of hGGPPS-WT in complex with the bisphosphonate ibandronate. Furthermore, to explore possible ortholog-dependent structural differences in metal–ligand coordination, we have reanalyzed eight previously solved structures of yGGPPS in complex with various bisphosphonates and assigned previously misidentified Mg^{2+} ions to the bisphosphonate binding site. Using a conjunction of drug-binding assays and computational docking, we show the essential role of Mg^{2+} ions stoichiometry in GGPPS–bisphosphonate interaction and the contribution of metal–ligand interactions to the predictivity of computational models for GGPPS inhibitors.

Materials and Methods

Overexpression and Purification of hGGPPS. cDNA of full-length human *GGPS1* (transOMIC, Huntsville, AL) was cloned into pETM-11 vector with N-terminal hexahistidine tag, followed by a tobacco etch virus (TEV) protease cleavage site. Proteins were overexpressed and purified, as previously described (Kavanagh et al., 2006a; Lisniansky et al., 2018), using immobilized metal affinity chromatography and size-exclusion chromatography. Briefly, *Escherichia coli* T7 express competent cells, transformed with the GGPPS construct, were grown in Terrific Broth medium at 37°C until reaching optical density_{600 nm} = 0.6 and induced at 16°C by adding 0.5 mM

isopropyl β -D-1-thiogalactopyranoside. Proteins were expressed at 16°C for 16 to 20 hours and harvested by centrifugation (10,000g for 10 minutes). Cells were suspended in buffer A, containing 50 mM HEPES, pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), 1 μ g/ml DNase I, 1 mM phenylmethane sulfonyl fluoride, and Protease Inhibitor Cocktail Set III (Calbiochem, San Diego, CA). The cells were disrupted in an EmulsiFlex C3 homogenizer (Avestin, Ottawa, ON, Canada). The soluble protein was then recovered by centrifugation at $\sim$ 32,000g for 45 minutes at 4°C. The supernatant was loaded onto a Ni²⁺-nitrilotriacetic acid column, followed by thorough washing with buffer A, supplemented with 30 mM imidazole to reduce nonspecific protein binding. Next, overexpressed proteins were eluted with buffer A supplemented with 250 mM imidazole. Imidazole was removed using a HiPrep 26/10 desalting column equilibrated with buffer A, followed by the addition of 6 $\times$ His-tagged TEV protease (1 mg TEV protease per 50 mg protein) to the eluate, to remove their 6 $\times$ His-tagged, at 4°C overnight. The cleaved proteins were then loaded again onto a Ni²⁺-nitrilotriacetic acid column pre-equilibrated with buffer A containing 30 mM imidazole to remove the cleaved 6 $\times$ His-tag and TEV protease. The flow-through was collected, concentrated to 3 to 4 ml, and loaded onto a HiLoad 16/60 Superdex-200 column (GE healthcare, UK) equilibrated with 10 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM MgCl₂, and 0.5 mM TCEP for final purification. Purified proteins were concentrated, flash-frozen in liquid nitrogen, and stored at -80°C .

Crystallization and Structure Determination of Ibandronate-Bound hGGPPS. Initial crystallization screens were performed using 38 mg/ml purified hGGPPS at 19°C using the sitting drop vapor diffusion method. Initial crystals were obtained in 0.1 M sodium formate, pH 7.0, 12% w/v PEG 3350. Crystals were soaked overnight with mother liquor solution supplemented with 350 μ M ibandronate, cryoprotected with 20% glycerol, and immersed in liquid N₂. Data were collected at 100°K at the European Synchrotron Radiation Facility (Grenoble, France). Integration, scaling, and merging of the diffraction data were done with the XDS program (Kabsch, 2010). As the data were slightly anisotropic, an ellipsoidal truncation and anisotropic scaling were performed (Strong et al., 2006) using resolution cutoffs of $a^* = 2.3$ Å, $b^* = 2.2$ Å, and $c^* = 2.2$ Å. The structure was solved by molecular replacement using the programs PHASER (McCoy et al., 2007) and PHENIX (Adams et al., 2010) (Table 1). The structure of a single dimer from GGPPS-WT [Protein Data Bank (PDB) 2Q80] was used as a search model. Iterative model building and refinement were carried out in PHENIX with manual adjustments using COOT (Emsley and Cowtan, 2004). Structural illustrations were prepared with University of California, San Francisco Chimera (<https://www.cgl.ucsf.edu/chimera>) or PyMOL (<https://pymol.org>). Atomic coordinates and structure factors for the structure of hGGPPS in complex with ibandronate have been deposited in the PDB with accession number 6R4V.

Assignment of Mg²⁺ Ions. To assign Mg²⁺ ions, we have used several restraints, including the average bond lengths, coordination number (CN), and the identity of the oxygen donors. The usual CN for Mg²⁺ in proteins is six, with one to two protein donor oxygen atoms and the rest arising from phosphate groups and water molecules. However, incomplete coordination spheres in medium resolution structures (2–2.5 Å), as the available structures of yGGPPS, are commonly observed. Therefore, we used the average CN (4.5 $\pm$ 1.5) in medium-resolution structures (Zheng et al., 2008) and considered binding sites with CN = 3–6. In addition, although based on the Cambridge Structural Database (Kennard, 2015), the average Mg²⁺-O bond length is 2.16 Å, in the given resolution range, and using a cutoff of 3 Å to define the coordination sphere, the mean Mg²⁺-O bond length is 2.24 $\pm$ 0.26 Å with a complete coordination sphere [coordination number (CN) $\geq$ 5] and 2.37 $\pm$ 0.32 Å with an incomplete coordination sphere (CN < 5) (Zheng et al., 2008). These bond length values were used as reference in the current analysis.

Differential Scanning Fluorimetry. Thermal shift assay was performed using a real-time polymerase chain reaction system

TABLE 1
Crystallographic statistics for hGGPPS in complex with ibandronate

Data Collection	
Space group	P2 ₁ 2 ₁ 2 ₁
Cell dimensions a,b,c (Å)	68.40, 152.80, 198.40
α,β,γ (°)	90, 90, 90
Beamline	ESRF ID30B
Wavelength (Å)	0.976
Resolution (Å)	2.2
Multiplicity	6.58
Completeness (%)	99.8
Mean I/ σ (I)	8.51
R _{meas} (%)	17.1
Refinement statistics	
No. reflections (work/free) ^a	98,591/5215
Resolution range ^a	49.66–2.20
R _{work} /R _{free}	0.1787/0.2245
No. atoms	
Macromolecules	13,678
Ligands	143
Solvent	1242
Average B-factor	
Macromolecules	36.3
Ligands	51.0
Solvent	43.0
RMSD (bond lengths)	0.005
RMSD (bond angles)	0.8
Ramachandran outliers (%)	0

ESRF, European Synchrotron Radiation Facility; RMSD, root-mean-square deviation.

^aAfter anisotropic scaling.

(Thermo Fisher Scientific, Waltham, MA) with the fluorescent dye SYPRO Orange (Thermo Fisher Scientific) using the ROX filter set in clear 96-well plates (Niesen et al., 2007). The temperature was increased using a continuous ramp at a rate of 1°C/min from 25°C to 95°C. Assays were performed in a final volume of 25 μ l, containing 5 μ M protein, 5X SYPRO Orange, 100 mM NaCl, 10 mM Na-HEPES, 1 mM MgCl₂, 0.5 mM TCEP, pH 7.5, and different bisphosphonate concentrations (0.25–500 μ M). Melting temperatures were extracted by Boltzmann sigmoidal fitting of the ascending phase of the curves. Bisphosphonates-concentration dependence of the melting temperature was fit using the Hill equation (Origin 7.0; OriginLab, Northampton, MA).

Computational Drug Docking. Coordinate files were prepared for molecular docking using the protein preparation wizard (Sastry et al., 2013) (Schrödinger, New York, NY). The protocol includes three stages, as follows: 1) addition of explicit hydrogens, bond order assignment, and building missing amino acid side chains; 2) determination of protonation state for protein side chains using Propka 3.1 (Olsson et al., 2011; Søndergaard et al., 2011); and 3) restrained energy minimization with 0.3 root-mean-square deviation cutoff for the heavy atoms. Ligprep (Schrödinger, New York, NY) was used to prepare the known inhibitors of GGPPS for molecular docking. Ionization states of ligands were determined at pH = 7.0 $\pm$ 2.0 using Epik 4.0 (Greenwood et al., 2010). In addition to the normal protonation states, Epik generated metal-binding states for each ligand. Molecular docking was performed using Glide 7.5 (Friesner et al., 2004; Halgren et al., 2004). The receptor grid was generated around the geometric center of the ligand found in the crystal structures, with 10 Å edges for the enclosing box. Ligands were docked with flexible conformer sampling and the standard precision-scoring function. The bisphosphonate core was restricted to the coordinates found in the crystal structure, with 0.5 Å tolerance for deviations. For each ligand, up to 10 different poses were generated, the pose with the lowest root-mean-square deviation in comparison with the crystalized ligand was selected, and binding energy was estimated with molecular mechanics combined with the generalized BornBB and surface area continuum solvation method. The above method calculates binding

energy using the following equation: $\Delta G_{\text{binding}} = G_{\text{complex}} - G_{\text{ligand}} - G_{\text{protein}}$. The internal energy is calculated using the molecular mechanics OPLS3 forcefield (Harder et al., 2016), whereas the desolvation energy and electrostatic interactions are calculated using Variable Dielectric and Surface Generalized Born (Li et al., 2011). To account for the differences between Glide's scoring function and molecular mechanics combined with the generalized Born and surface area continuum solvation method energies, the ligand pose was optimized using energy minimization prior to the binding energy determination. Correlations between the calculated binding energies and the experimentally obtained values were calculated using the Pearson correlation coefficient.

Results

Crystal Structure of hGGPPS in Complex with a Bisphosphonate. Bisphosphonates are used clinically in humans mainly for the treatment of osteoporosis (Russell, 2011). Although bisphosphonates are known to inhibit GGPPS, the structure of WT hGGPPS-bisphosphonate complex remained unresolved (Lisnyansky et al., 2018). Importantly, the main molecular blueprint for designing novel bisphosphonate for GGPPS inhibition is the well-characterized yGGPPS ortholog. Nevertheless, it was shown that bisphosphonates exhibit different affinities toward hGGPPS and yGGPPS, and their potency distributions differ for each enzyme (Guo et al., 2007). Interestingly, in some cases the affinities differ by a factor of 20 between the enzymes, whereas in other cases, the affinities are practically identical. Therefore, to unveil the molecular details of hGGPPS-bisphosphonate

interaction, we determined the 2.2 Å resolution crystal structure of hGGPPS in the presence of ibandronate (Fig. 2; Supplemental Fig. 1; Supplemental Material 1; Table 1).

Similar to the previously reported structure of hGGPPS bound to GGPP (PDB 2Q80), the biologic assembly consists of a hexamer, composed of a trimer of dimers (Fig. 2A) (Kavanagh et al., 2006a). Moreover, the structures share high similarity, as reflected by a low root-mean-square deviation value (0.63 Å) for the entire hexameric assembly, indicating that the binding of ibandronate does not induce major conformational transitions. Within the dimers, each monomer exhibits the canonical *trans*-prenyltransferase fold, composed of 13 α -helices. Ten of the 13 α -helices surround a large central cavity, where the aspartate-rich conserved sequence tandem, forming the FPP and bisphosphonate binding sites, are localized (Liang et al., 2002).

Focusing on the bisphosphonate binding sites, we could identify three Mg^{2+} ions in five of six chains and two Mg^{2+} ions in one chain (Fig. 2B; Supplemental Fig. 2). This is in contrast to the coordination of GGPP, which includes only two Mg^{2+} ions (Kavanagh et al., 2006a). The Mg^{2+} ions in the hGGPPS-ibandronate structure are well coordinated, with an average Mg^{2+} -O bond length of 2.19 ± 0.21 Å and a CN of 5.7 ± 0.6 (range 4–6) for the entire hexamer. The Mg1 site is coordinated by two oxygens from the phosphate group, two carboxyl oxygens from D64 and D68, and two water molecules (Fig. 2C). The Mg2 site is coordinated by one oxygen from the phosphate group, two carboxyl oxygens from D64 and D68, and three water molecules (Fig. 2D). The Mg3 site is

Fig. 2. Crystal structure of hGGPPS in complex with ibandronate. (A) The asymmetric unit, containing the biologic hexameric arrangement of ibandronate-bound hGGPPS, in cartoon representation. (B) Surface representation of one monomer colored according to the adaptive Poisson-Boltzmann solver surface electrostatics. The rectangle frames a zoom perspective of the ibandronate-binding pocket. Ibandronate and residues interacting with the Mg^{2+} ions (purple spheres) are shown as sticks. Water molecules are shown as red spheres. (C–E) The three Mg^{2+} binding sites, Mg1 (C), Mg2 (D), and Mg3 (E), are shown with their electron density contoured at 1.3σ (blue mesh).

coordinated by two oxygens from the phosphate group, one carboxyl oxygen from D188, and three water molecules (Fig. 2E). Overall, each Mg^{2+} ion is coordinated by one to two protein donors, one to two phosphate group donors, and two to three water molecules, matching the coordination observed in most Mg^{2+} -protein complexes (Zheng et al., 2008; Harding et al., 2010). In summary, the first crystal structure of a hGGPPS-bisphosphonate complex clearly supports the notion that three Mg^{2+} ions are involved in the coordination of bisphosphonates by hGGPPS.

Effect of Mg^{2+} Ion Stoichiometry on Drug Docking to hGGPPS. Next, we sought to assess the predictivity of our hGGPPS-ibandronate structure as a model for computational drug screening, and to determine the significance of Mg^{2+} ions in hGGPPS-bisphosphonate interactions. To that end, we surveyed clinically available bisphosphonates and predicted their binding energies to the hGGPPS structure with Mg^{2+} ions occupying all three sites (Table 2). To assess the contribution of Mg3, which was not resolved in one of the chains and is also absent in several yGGPPS structures (Guo et al., 2007) (see below), we also performed this analysis with Mg^{2+} ions occupying only sites Mg1 and Mg2 (Table 2). Next, we used our previously described thermal shift assay to measure the binding affinities of six commercially available bisphosphonates to hGGPPS (Fig. 3A; Supplemental Fig. 3; Table 2) (Lisnyansky et al., 2018). Strikingly, in the presence of all three Mg^{2+} ions, the calculated binding energies are highly correlated with the measured K_d values ($R^2 = 0.93$, $P = 0.002$, Fig. 3B). In sharp contrast, removal of the Mg^{2+} ion from the Mg3 site resulted in deterioration of the models predictivity, resulting in poor correlation of the calculated binding energies with the measured K_d values ($R^2 = 0.33$, $P = 0.23$, Fig. 3C).

Notably, the range of the measured K_d values obtained for the commercially available compounds is rather narrow. Thus, we expanded our analysis by correlating previously reported IC_{50} values (Szabo et al., 2002), spanning three orders of magnitude, with calculated binding energies in the presence of three or two Mg^{2+} ions (Fig. 4A; Table 3). Again, a statistically significant correlation was obtained in the presence of all three Mg^{2+} ions between the calculated binding energies and the experimental IC_{50} values ($R^2 = 0.62$, $P < 0.0001$, Fig. 4A). Removal of the Mg^{2+} ion from the Mg3 site resulted in poor, nonsignificant correlation of the calculated binding energies with the experimental IC_{50} values ($R^2 = 0.14$, $P = 0.075$, Fig. 4B). Thus, the structure of hGGPPS, solved in this study, is a highly useful model for

computational drug-docking studies. Moreover, the presence of Mg^{2+} ions in all three sites is imperative for ligand-protein interactions, and their assignment is a crucial prerequisite for successful docking.

Reanalysis of yGGPPS-Bisphosphonate Complexes. We have previously reanalyzed the structure of the dimeric yGGPPS in complex with zoledronate (PDB 2E91) and were able to identify three Mg^{2+} ions in each monomer (Lisnyansky et al., 2018) with a coordination scheme similar to that reported in this study for hGGPPS in complex with ibandronate (Figs. 2B and 5A; Supplemental Material 2). Importantly, two yGGPPS structures, in complex with BPH-252 (PDB 2Z4X, Supplemental Material 3) and BPH-23 (PDB 2Z52, Supplemental Material 4), were originally assigned with three Mg^{2+} ions per monomer. Thus, we decided to re-examine additional deposited structures of yGGPPS (Supplemental Table 1) with a goal of identifying previously unassigned Mg^{2+} ions. Although the number of Mg^{2+} ions per monomer in the deposited structure varied between zero to three, we were able to assign three Mg^{2+} ions in all the re-refined structures (Supplemental Fig. 4; Table 4). The structural validity of this analysis is supported by improvement in the crystallographic statistics, with significant decrease in R_{free} , markedly improved model stereochemistry, and elimination of all the Ramachandran outliers in the deposited structures (Supplemental Table 1).

First, we analyzed deposited structures without any Mg^{2+} ions present. Given the surface electrostatics of the binding pocket (Fig. 2B), encompassing the aspartate-rich motifs, and of the phosphate groups, the absence of Mg^{2+} ions seemed highly unlikely. Indeed, although the original structures included no ions, we could position three Mg^{2+} ions in each chain (six ions in total) of yGGPPS-BPH806 (PDB 2Z78, Supplemental Material 5) and yGGPPS-BPH-sc01 (PDB 2Z4Z, Supplemental Material 6) (Supplemental Fig. 4). In these cases, the average Mg^{2+} -O bond distances are 2.40 ± 0.25 Å (yGGPPS-BPH-806) and 2.23 ± 0.25 Å (yGGPPS-BPH-sc01), and in each structure five Mg^{2+} ions have $\text{CN} \geq 5$ and one ion has $\text{CN} < 5$ (Table 4).

Next, we analyzed deposited structures with two Mg^{2+} ions, similar to the case of yGGPPS-zoledronate (PDB 2E91). We have re-refined the structures of yGGPPS-minodronate (PDB 2E92, Supplemental Material 7) and yGGPPS-BPH-675 (PDB 2E95, Supplemental Material 8), with Mg^{2+} ions assigned only at position Mg1 and Mg2, leaving the Mg3 site vacant. For yGGPPS-minodronate, following addition of Mg3 to both chains, the average Mg^{2+} -O bond distance was 2.17 ± 0.13 Å, where three of the Mg^{2+} ions have $\text{CN} = 5$ and three Mg^{2+} ions have $\text{CN} = 4$ (Supplemental Fig. 4; Table 4). Similarly, following addition of Mg3 to both chains of yGGPPS-BPH-675, the average Mg^{2+} -O bond distance is 2.14 ± 0.12 Å, where all Mg^{2+} ions have $\text{CN} \geq 5$ (Supplemental Fig. 4; Table 4).

Finally, we re-analyzed yGGPPS-BPH-210 (PDB 2Z7H, Supplemental Material 9), where Mg^{2+} binding differed between the chains: a single Mg^{2+} ion was assigned to one monomer and no ions were assigned to the second monomer. As in the abovementioned structures, we could readily add five additional ions in total, with three Mg^{2+} ions assigned to each chain (Supplemental Fig. 4). The average Mg^{2+} -O bond distance is 2.24 ± 0.23 Å, where all Mg^{2+} ions have $\text{CN} \geq 5$ (Table 4). Overall, we could identify three Mg^{2+} ions per monomer in all of the re-refined structures presented in this

TABLE 2
Experimental and calculated binding parameters of bisphosphonates to hGGPPS

ΔG values were calculated as described in *Materials and Methods*. The average ΔT_m and K_d values are shown as average $\pm$ S.D., $n = 6$ for all the experiments.

Bisphosphonate	ΔT_m	K_d (μM)	Calculated ΔG (Kcal/mol)	
			3 Mg^{2+}	2 Mg^{2+}
Ibandronate	23.9 ± 0.6	1.74 ± 0.22	21.1	22.1
Zoledronate	19.6 ± 0.4	2.76 ± 0.31	25.3	30.8
Alendronate	16.0 ± 0.2	3.03 ± 0.21	30.3	36.2
Risedronate	16.8 ± 0.3	3.35 ± 0.30	30.6	48.4
Neridronate	17.4 ± 0.3	3.51 ± 0.30	32.1	31.5
Pamidronate	15.8 ± 0.3	4.40 ± 0.45	34.1	33.3

T_m , melting temperature.

Fig. 3. Effect of Mg^{2+} stoichiometry on computational docking of commercial bisphosphonates to hGGPPS. (A) Differential scanning fluorimetry thermal shift assay in the presence of increasing bisphosphonate concentrations presented as T_m difference. Experiments were performed as outlined in *Materials and Methods*. Data are presented as mean $\pm$ S.D., $n = 6$. (B and C) Correlation between measured K_i values (micromolar) and calculated binding energies (Kilocalorie per mole) obtained with Mg^{2+} ions occupying all three Mg^{2+} sites (B) or only sites Mg1 and Mg2 (C).

work (Table 4), with an average CN = 5.5 ± 0.7 (range = 3–6) and average Mg^{2+} -O bond length = 2.18 ± 0.20 Å, which closely match the expected values for Mg^{2+} ion coordination (Table 4). Thus, re-refinement of these structures uncovers a previously misidentified canonical binding scheme, demonstrating that, similar to hGGPPS, bisphosphonate binding to yGGPPS necessitates three Mg^{2+} ions (Supplemental Fig. 4; Table 4).

Effect of Mg^{2+} Ion Stoichiometry on Drug Docking to yGGPPS. To further validate the assignment of Mg^{2+} ions to the yGGPPS structures, and to generalize the functional significance of the metal–ligand stoichiometry, we performed additional virtual docking of bisphosphonates with known K_i values toward yGGPPS (PDB 2E91) (Fig. 5; Table 5) (Guo et al., 2007). As in hGGPPS, to assess the contribution of Mg3, we performed this analysis with Mg^{2+} ions occupying all binding sites or only sites Mg1 and Mg2 (Table 5). Consistent with our crystallographic analysis (Fig. 5A; Supplemental Fig. 4), in the presence of all three Mg^{2+} ions, the calculated binding energies are highly correlated with the measured K_i values ($R^2 = 0.71$, $P = 0.0042$, Fig. 5B). However, leaving the Mg3 site vacant appreciably hindered the correlation between the calculated binding energies and the experimental K_i values ($R^2 = 0.44$, $P = 0.052$, Fig. 5C). Thus, a three Mg^{2+} ion stoichiometry is common and essential for binding of bisphosphonates to both yGGPPS and hGGPPS.

Discussion

The goals of the present study were to elucidate the structural basis of bisphosphonates interaction with hGGPPS and to determine the accurate metal–ligand interaction network underlying GGPPS–bisphosphonate binding. In addition, given that mevalonate pathway enzymes, and

specifically GGPPS, were highlighted in recent years as potential drug targets (Andela et al., 2003; Jiang et al., 2014; Gruenbacher and Thurnher, 2015), we sought to provide a reliable model for future drug design and screening. Importantly, preclinical studies have established the potential use of GGPPS inhibitors in the treatment of solid and hematologic malignancies, such as lung alveolar carcinoma (Andela et al., 2003), breast cancer (Ginestier et al., 2012), multiple myeloma (Lachay et al., 2018), metastatic prostate cancer (Reilly et al., 2015, 2017), and *KRAS*-mutant lung cancer (Xia et al., 2014). Moreover, GGPPS enzymes from parasites leading to human diseases such as malaria, Chagas disease, leishmaniasis, and toxoplasmosis are considered as potential drug targets, as bisphosphonates were shown to inhibit parasitic growth in vitro and in vivo (Szabo et al., 2002; G Ricci et al., 2016). Collectively, these data establish the clinical potential of GGPPS inhibitors.

Despite the promising preclinical results of GGPPS inhibitors, bisphosphonates have several shortcomings, currently preventing their clinical use in the treatment of nonskeletal diseases. Their main disadvantages relate to their pharmacokinetics, with limited distribution focused mainly to the bone matrix (Lin, 1996). In addition, some bisphosphonates lack specificity toward GGPPS (Guo et al., 2007), and most of them display poor cell permeability (Haney et al., 2017). Therefore, the design of novel bisphosphonates with improved tissue distribution profiles, such as the lipophilic bisphosphonates (Zhang et al., 2009), bisphosphonates with improved GGPPS specificity (Zhou et al., 2014; Wills et al., 2015, 2017), and nonbisphosphonate GGPPS inhibitors, is highly desired (Merino et al., 2017). However, these translational efforts are hampered by the current ambiguity in metal–ligand interaction assignment within the binding site (Guo et al., 2007; K-M Chen et al., 2008; Zhang et al., 2009), a problem

Fig. 4. Extended analysis of Mg^{2+} effect on computational docking of bisphosphonates to hGGPPS. (A and B) Correlation between measured IC_{50} values (micromolar) [reported by Szabo et al. (2002)] and calculated binding energies (Kilocalorie per mole) obtained with Mg^{2+} ions occupying all three Mg^{2+} sites (A) or only sites Mg1 and Mg2 (B).

TABLE 3

Experimental IC_{50} values and calculated binding energies of bisphosphonates to hGGPPS

IC_{50} were obtained from Szabo et al. (2002). For full description of the compounds, please refer to the original publication. ΔG values were calculated as described in *Materials and Methods*.

Bisphosphonate	IC_{50} (μM)	Calculated ΔG (Kcal/mol)	
		3 Mg^{2+}	2 Mg^{2+}
14	0.92	0.22	31.63
15	1.4	0.02	22.84
16	0.72	8.92	41.94
17	4.3	21.05	30.49
18	11	18.44	36.45
19	53	16.74	34.55
20	200	17.32	34.07
21	620	20.09	38.45
22	180	28.76	44.18
23	220	25.19	42.65
24	220	22.48	39.44
25	220	28.58	31.15
26	260	31.05	28.52
27	350	22.63	42.69
28	410	30.93	40.82
29	550	27.78	37.25
30	2.2	10.04	20.47
31	19	6.77	8.52
32	83	10.64	21.01
33	330	24.42	32.05
34	690	19.87	36.01
35	440	23.72	33.29
36	180	27.95	45.70

common to other metalloenzymes as well (Puerta et al., 2003). This ambiguity impedes the ability of quantitative computational drug screening to predict protein–ligand interactions (Sommerhalter et al., 2005; Riccardi et al., 2018).

Although numerous yGGPPS structures in complex with different bisphosphonates are available, the affinity of these compounds toward hGGPPS and yGGPPS differs. For example, although the reported affinities of zoledronate and minodronate to yGGPPS are ~ 10 -fold higher compared with hGGPPS, and the affinity of BPH-364 to yGGPPS is ~ 25 -fold higher compared with hGGPPS, the affinity of other bisphosphonates such as BPH-628 and BPH-675 is practically identical for both orthologs (Guo et al., 2007). In this study, to provide a structural framework for the design of novel bisphosphonates for hGGPPS inhibition, we determined the first crystal structure of hGGPPS in complex with a bisphosphonate (Fig. 2). Our 2.2 Å resolution crystal structure clearly resolved the hGGPPS–bisphosphonate binding mode, involving three Mg^{2+} ions. Rummaging through the Protein Data Bank (PDB), we found this binding mode only in two

yGGPPS–bisphosphonate complexes, but other metal stoichiometries ranging from zero to two Mg^{2+} ions were reported in most structures (of which we have reanalyzed six and assigned the canonical three Mg^{2+} ions) (Guo et al., 2007; K-M Chen et al., 2008; Zhang et al., 2009). Thus, we sought to determine whether the binding stoichiometry observed in this study for hGGPPS is a bona fide prerequisite for bisphosphonate binding, or if different bisphosphonates display different metal–ligand binding schemes.

Although X-ray crystallography is the gold standard for high-resolution structural investigations, it should be kept in mind that the reported crystal structures are only models that explain the electron density, and are subjected to interpretation by the crystallographer (Davis et al., 2003). The presence of metals, and specifically Mg^{2+} , within ligand binding sites poses challenges in interpretation of the crystallographic data (Handing et al., 2018). First, Mg^{2+} has the same number of electrons as water, rendering them indistinguishable merely by their electron density. Thus, automatic assignment of water molecules to the model (Adams et al., 2010), developed to facilitate structure determination, may become a double-edged sword by introducing bias and hampering the detection of other solvents such as Mg^{2+} , Na^+ , or NH_4^+ (Davis et al., 2003), unless the added water molecules are critically examined. Moreover, the wavelength required to detect Mg^{2+} by anomalous diffraction, an approach commonly used to identify other metals in metalloenzymes, is outside the wavelength range obtainable in modern synchrotrons (Zheng et al., 2008, 2015; Harding et al., 2010). Indeed, previous studies of structures deposited in the PDB revealed misidentification of Mg^{2+} ions in complex with RNA (Zheng et al., 2015) or with metalloproteins (Zheng et al., 2008), including placement of Mg^{2+} instead of Ca^{2+} , Na^+ , or water and vice versa. The incorrect placement of Mg^{2+} within the binding pocket of metalloenzymes has clear implications on subsequent computational drug screening and design. As we show in this study, the omission of a single Mg^{2+} ion from the bisphosphonate-binding scheme of either hGGPPS or yGGPPS results in poor model predictivity (Figs. 3–5). These results emphasize the importance of metal–ligand interactions in computational drug screening and design in GGPPS and other metalloenzymes in general.

Of note, the calculated ΔG values were positive, which indicates that the ligands would not bind, in stark conflict with reality. A close examination of the energy decomposition indicates that this is due to an overestimate of the electrostatic desolvation component of the binding free energy (Kessel and Ben-Tal, 2018), caused by the numerous charges on both the ligands and protein binding site.

TABLE 4

Mg^{2+} coordination parameters in re-refined structures of yGGPPS

The average Mg^{2+} -O bond length is shown as average $\pm$ S.D.; numbers in parentheses indicate the sample size.

Ligand	PDB	Mg^{2+} /Chain (Deposited)	Mg^{2+} /Chain (Re-refined)	Mg^{2+} -O Bond Length (Å)	CN ≥ 5	CN < 5
Zoledronate	2E91	2	3	2.09 ± 0.13 (34)	6	0
Minodronate	2E92	2	3	2.17 ± 0.13 (27)	3	3
BPH-675	2E95	2	3	2.14 ± 0.12 (35)	6	0
BPH-210	2Z7H	0/1	3	2.24 ± 0.23 (33)	6	0
BPH-806	2Z78	0	3	2.40 ± 0.25 (31)	5	1
BPH-sc01	2Z4Z	0	3	2.23 ± 0.25 (31)	5	1
BPH-252	2Z4X	3	3	2.11 ± 0.10 (36)	6	0
BPH-23	2Z52	3	3	2.10 ± 0.17 (36)	6	0

Fig. 5. Effect of Mg^{2+} stoichiometry on computational docking of bisphosphonates to yGGPPS. (A) Cartoon representations of the ligand-binding pocket in the deposited zoledronate-bound yGGPPS (PDB 2E91, upper panel) and the re-refined structure (lower panel). Zoledronate and residues interacting with the Mg^{2+} ions (purple spheres) are shown as sticks. Water molecules are shown as red spheres. (B and C) Correlation between reported K_i values (nanomolar) and calculated binding energies (Kilocalorie per mole) obtained with Mg^{2+} ions occupying all three Mg^{2+} sites (B) or only sites Mg1 and Mg2 (C).

However, as all the molecules compared in this study share similar structure and as the protein structure changes vary little when binding different bisphosphonates (Guo et al., 2007), the error is subtracted out when comparing the relative values as observed in the slopes (Figs. 3–5), even though the absolute ΔG values are consistently too positive.

In light of the computational docking results, which decisively favored three Mg^{2+} ions in the bisphosphonate coordination scheme (Figs. 3 and 4), we pursued a comprehensive reanalysis of previously deposited yGGPPS structures representing the four possible Mg^{2+} binding stoichiometries (Fig. 5). Using a set of stereochemical restraints, including bond lengths, identity of oxygen donors, and CN, we could place three Mg^{2+} ions in all the re-refined structures presented in this study (Table 4). Importantly, the overall bonding parameters were as expected based on the Cambridge Structural Database and structures with similar resolution deposited in the PDB (Zheng et al., 2008). Together, our experimental and computational findings reiterate that Mg^{2+} ions should be carefully placed in crystallographic structures based on the binding site geometry.

In conclusion, using the combination of experimental and computational approaches, we have established the metal coordination network mediating bisphosphonate–GGPPS interactions. Our data underscore the importance of three Mg^{2+} ions for drug binding and their essential role in drug screening and design. This work provides a structural basis

for future rational design of additional MBP-harboring drugs targeting hGGPPS.

Supporting Information. There are crystallographic statistics for the re-refined yGGPPS structures (Supplemental Table 1), crystal packing (Supplemental Fig. 1), Mg^{2+} ions omit map (Supplemental Fig. 2), representative fluorescence–temperature relations of GGPPS in the presence of different ibandronate concentrations (Supplemental Fig. 3), comparison of the deposited, and re-refined yGGPPS-binding pockets (Supplemental Fig. 4). The structure of hGGPPS in complex with ibandronate and the re-refined yGGPPS structures are available as Supplemental Materials.

Acknowledgments

We thank the staff of ID30B at the European Synchrotron Radiation Facility for assistance with diffraction experimentation. This work was performed in partial fulfillment of the requirements for a Ph.D. degree of M.L. and a M.D. degree of O.S. (Sackler Faculty of Medicine, Tel Aviv University, Israel). We acknowledge the Edmund J. Safra Center for Bioinformatics at Tel Aviv for supporting E.Y.'s fellowship.

Authorship Contributions

Participated in research design: Giladi, Haitin.
Conducted experiments: Lisnyansky, Yariv, Segal, Marom.
Contributed new reagents or analytic tools: Loewenstein, Ben-Tal.
Performed data analysis: Lisnyansky, Giladi, Haitin.
Wrote or contributed to the writing of the manuscript: Lisnyansky, Giladi, Haitin.

References

- Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**:213–221.
- Andela VB, Pirri M, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosenblatt JD, and Rosier RN (2003) The mevalonate synthesis pathway as a therapeutic target in cancer. *Clin Orthop Relat Res* **415S**:S59–S66.
- Bourne HR, Sanders DA, and McCormick F (1990) The GTPase superfamily: a conserved switch for diverse cell functions. *Nature* **348**:125–132.
- Bruno E, Buemi MR, Di Fiore A, De Luca L, Ferro S, Angeli A, Cirilli R, Sadutto D, Alterio V, Monti SM, et al. (2017) Probing molecular interactions between human carbonic anhydrases (hCAs) and a novel class of benzenesulfonamides. *J Med Chem* **60**:4316–4326.
- Cohen SM (2017) A bioinorganic approach to fragment-based drug discovery targeting metalloenzymes. *Acc Chem Res* **50**:2007–2016.
- Davis AM, Teague SJ, and Kleywegt GJ (2003) Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. *Angew Chem Int Ed Engl* **42**:2718–2736.
- Downward J (2003) Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer* **3**:11–22.
- Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* **60**:2126–2132.

TABLE 5

Experimental and calculated binding parameters of bisphosphonates to yGGPPS

K_i values were obtained from Guo et al. (2007). For full description of the compounds, please refer to the original publication. ΔG values were calculated as described in *Materials and Methods*.

Bisphosphonate	Experimental K_i (nM)	Calculated ΔG (Kcal/mol)	
		3 Mg^{2+}	2 Mg^{2+}
BPH-364	10	21.1	14.4
BPH-628	30	27.5	27.5
BPH-676	30	24.9	19.1
BPH-608	60	39.1	33.3
BPH-675	80	31.4	26.4
BPH-629	110	51.0	44.4
BPH-210	115	30.7	14.5
Minodronate	130	45.3	29.0
Zoledronate	260	57.9	51.4

- Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J Med Chem* **47**:1739–1749.
- Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, et al. (2012) Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. *Stem Cells* **30**:1327–1337.
- Greenwood JR, Calkins D, Sullivan AP, and Shelley JC (2010) Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. *J Comput Aided Mol Des* **24**:591–604.
- G Ricci C, Liu YL, Zhang Y, Wang Y, Zhu W, Oldfield E, and McCammon JA (2016) Dynamic structure and inhibition of a malaria drug target: geranylgeranyl diphosphate synthase. *Biochemistry* **55**:5180–5190.
- Gruenbacher G and Thurnher M (2015) Mevalonate metabolism in cancer. *Cancer Lett* **356**:192–196.
- Guo R-T, Cao R, Liang P-H, Ko T-P, Chang T-H, Hudock MP, Jeng W-Y, Chen CK-M, Zhang Y, Song Y, et al. (2007) Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. *Proc Natl Acad Sci USA* **104**:10022–10027.
- Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, and Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *J Med Chem* **47**:1750–1759.
- Handing KB, Niedzialkowska E, Shabalin IG, Kuhn ML, Zheng H, and Minor W (2018) Characterizing metal-binding sites in proteins with X-ray crystallography. *Nat Protoc* **13**:1062–1090.
- Haney SL, Wills VS, Wiemer DF, and Holstein SA (2017) Recent advances in the development of mammalian geranylgeranyl diphosphate synthase inhibitors. *Molecules* **22**:E886.
- Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL, et al. (2016) OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. *J Chem Theory Comput* **12**:281–296.
- Harding MM, Nowicki MW, and Walkinshaw MD (2010) Metals in protein structures: a review of their principal features. *Crystalllogr Rev* **16**:247–302.
- Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, et al. (2014) In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. *Br J Cancer* **111**:1562–1571.
- Jiang Z, You Q, and Zhang X (2019) Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: a perspective. *Eur J Med Chem* **165**:172–197.
- Kabsch W (2010) XDS. *Acta Crystallogr D Biol Crystallogr* **66**:125–132.
- Kavanagh KL, Dunford JE, Bunkoczi G, Russell RGG, and Oppermann U (2006a) The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. *J Biol Chem* **281**:22004–22012.
- Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RGG, and Oppermann U (2006b) The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. *Proc Natl Acad Sci USA* **103**:7829–7834.
- Kennard O (2015) Cambridge crystallographic database. *Acta Crystallogr A* **37**:C343.
- Kessel A and Ben-Tal N (2018) *Introduction to Proteins: Structure, Function, and Motions*, 2nd ed, Taylor & Francis, Boca Raton, FL.
- K-M Chen C, Hudock MP, Zhang Y, Guo RT, Cao R, No JH, Liang PH, Ko TP, Chang TH, Chang SC, et al. (2008) Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. *J Med Chem* **51**:5594–5607.
- Konstantinopoulos PA, Karamouzis MV, and Papavassiliou AG (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. *Nat Rev Drug Discov* **6**:541–555.
- Lachay AM, Waller DD, Park J, Gómez Palou M, Vincent F, Huang XF, Ta V, Berghuis AM, Sebag M, and Tsantrizos YS (2018) Unraveling the prenylation-cancer paradox in multiple myeloma with novel geranylgeranyl pyrophosphate synthase (GGPPS) inhibitors. *J Med Chem* **61**:6904–6917.
- Li J, Abel R, Zhu K, Cao Y, Zhao S, and Friesner RA (2011) The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. *Proteins* **79**:2794–2812.
- Liang PH, Ko TP, and Wang AH (2002) Structure, mechanism and function of prenyltransferases. *Eur J Biochem* **269**:3339–3354.
- Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. *Bone* **18**:75–85.
- Lisnyansky M, Kapelushnik N, Ben-Bassat A, Marom M, Loewenstein A, Khanashvili D, Giladi M, and Haitin Y (2018) Reduced activity of geranylgeranyl diphosphate synthase mutant is involved in bisphosphonate-induced atypical fractures. *Mol Pharmacol* **94**:1391–1400.
- McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. *J Appl Cryst* **40**:658–674.
- Merino P, Maiuolo L, Delso I, Algieri V, De Nino A, and Tejero T (2017) Chemical approaches to inhibitors of isoprenoid biosynthesis: targeting farnesyl and geranylgeranyl pyrophosphate synthases. *RSC Adv* **7**:10947–10967.
- Mullen PJ, Yu R, Longo J, Archer MC, and Penn LZ (2016) The interplay between cell signalling and the mevalonate pathway in cancer. *Nat Rev Cancer* **16**:718–731.
- Nayal M and Di Cera E (1996) Valence screening of water in protein crystals reveals potential Na⁺ binding sites. *J Mol Biol* **256**:228–234.
- Niesen FH, Berglund H, and Vedadi M (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. *Nat Protoc* **2**:2212–2221.
- Olsson MH, Søndergaard CR, Rostkowski M, and Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. *J Chem Theory Comput* **7**:525–537.
- Puerta DT, Schames JR, Henchman RH, McCammon JA, and Cohen SM (2003) From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery. *Angew Chem Int Ed Engl* **42**:3772–3774.
- Reilly JE, Neighbors JD, and Hohl RJ (2017) Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. *Cancer Biol Ther* **18**:872–882.
- Reilly JE, Neighbors JD, Tong H, Henry MD, and Hohl RJ (2015) Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. *Clin Exp Metastasis* **32**:555–566.
- Riccardi L, Genna V, and De Vivo M (2018) Metal–ligand interactions in drug design. *Nat Rev Chem* **2**:100–112.
- Russell RGG (2011) Bisphosphonates: the first 40 years. *Bone* **49**:2–19.
- Sastry GM, Adzhigirey M, Day T, Annabhimoju R, and Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J Comput Aided Mol Des* **27**:221–234.
- Sommerhalter M, Lieberman RL, and Rosenzweig AC (2005) X-ray crystallography and biological metal centers: is seeing believing? *Inorg Chem* **44**:770–778.
- Søndergaard CR, Olsson MH, Rostkowski M, and Jensen JH (2011) Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values. *J Chem Theory Comput* **7**:2284–2295.
- Strong M, Sawaya MR, Wang S, Phillips M, Cascio D, and Eisenberg D (2006) Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* **103**:8060–8065.
- Szabo CM, Matsumura Y, Fukura S, Martin MB, Sanders JM, Sengupta S, Cieslak JA, Loftus TC, Lea CR, Lee HJ, et al. (2002) Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. *J Med Chem* **45**:2185–2196.
- Wang M and Casey PJ (2016) Protein prenylation: unique fats make their mark on biology. *Nat Rev Mol Cell Biol* **17**:110–122.
- Wills VS, Allen C, Holstein SA, and Wiemer DF (2015) Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase. *ACS Med Chem Lett* **6**:1195–1198.
- Wills VS, Metzger JI, Allen C, Varney ML, Wiemer DF, and Holstein SA (2017) Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. *Bioorg Med Chem* **25**:2437–2444.
- Xia Y, Liu YL, Xie Y, Zhu W, Guerra F, Shen S, Yeddula N, Fischer W, Low W, Zhou X, et al. (2014) A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. *Sci Transl Med* **6**:263ra161.
- Zhang Y, Cao R, Yin F, Hudock MP, Guo RT, Krysiak K, Mukherjee S, Gao YG, Robinson H, Song Y, et al. (2009) Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. *J Am Chem Soc* **131**:5153–5162.
- Zheng H, Chruszcz M, Lasota P, Lebioda L, and Minor W (2008) Data mining of metal ion environments present in protein structures. *J Inorg Biochem* **102**:1765–1776.
- Zheng H, Shabalin IG, Handing KB, Bujnicki JM, and Minor W (2015) Magnesium-binding architectures in RNA crystal structures: validation, binding preferences, classification and motif detection. *Nucleic Acids Res* **43**:3789–3801.
- Zhou X, Ferree SD, Wills VS, Born EJ, Tong H, Wiemer DF, and Holstein SA (2014) Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. *Bioorg Med Chem* **22**:2791–2798.

Address correspondence to: Dr. Moshe Giladi, Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. E-mail: moshegil@post.tau.ac.il; or Dr. Yoni Haitin, Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. E-mail: yhaitin@post.tau.ac.il